Display options
Cite
Nagaharu K, Ikemura K, Yamashita Y, et al. A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity. Case Rep Oncol Med. 2016;2016:7510901doi: 10.1155/2016/7510901.
Nagaharu, K., Ikemura, K., Yamashita, Y., Oda, H., Ishihara, M., Sugawara, Y., Tamaru, S., Mizuno, T., & Katayama, N. (2016). A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity. Case reports in oncological medicine, 20167510901. https://doi.org/10.1155/2016/7510901
Nagaharu, Keiki, et al. "A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity." Case reports in oncological medicine vol. 2016 (2016): 7510901. doi: https://doi.org/10.1155/2016/7510901
Nagaharu K, Ikemura K, Yamashita Y, Oda H, Ishihara M, Sugawara Y, Tamaru S, Mizuno T, Katayama N. A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity. Case Rep Oncol Med. 2016;2016:7510901. doi: 10.1155/2016/7510901. Epub 2016 Apr 19. PMID: 27195162; PMCID: PMC4853945.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol Med. 2016;2016:7510901. doi: 10.1155/2016/7510901. Epub 2016 Apr 19.

A Case of Hyperammonemia Associated with High Dihydropyrimidine Dehydrogenase Activity.

Case reports in oncological medicine

Keiki Nagaharu, Kenji Ikemura, Yoshiki Yamashita, Hiroyasu Oda, Mikiya Ishihara, Yumiko Sugawara, Satoshi Tamaru, Toshiro Mizuno, Naoyuki Katayama

Affiliations

  1. Department of Hematology and Oncology, Suzuka General Hospital, Yamanohana, Yasuzuka, Suzuka, Mie Prefecture 1275-53, Japan.
  2. Department of Pharmacy, Mie University Hospital, Edobashi 2-174, Tsu, Mie Prefecture 514-8507, Japan.
  3. Department of Hematology and Oncology, Mie University Graduate School of Medicine, Edobashi 2-174, Tsu, Mie Prefecture 514-8507, Japan.

PMID: 27195162 PMCID: PMC4853945 DOI: 10.1155/2016/7510901

Abstract

Over the past decades, 5-Fluorouracil (5-FU) has been widely used to treat several types of carcinoma, including esophageal squamous cell carcinoma. In addition to its common side effects, including diarrhea, mucositis, neutropenia, and anemia, 5-FU treatment has also been reported to cause hyperammonemia. However, the exact mechanism responsible for 5-FU-induced hyperammonemia remains unknown. We encountered an esophageal carcinoma patient who developed hyperammonemia when receiving 5-FU-containing chemotherapy but did not exhibit any of the other common adverse effects of 5-FU treatment. At the onset of hyperammonemia, laboratory tests revealed high dihydropyrimidine dehydrogenase (DPD) activity and rapid 5-FU clearance. Our findings suggested that 5-FU hypermetabolism may be one of the key mechanisms responsible for hyperammonemia during 5-FU treatment.

References

  1. J Int Med Res. 2010 Jul-Aug;38(4):1313-23 - PubMed
  2. Jpn J Clin Oncol. 2006 Jan;36(1):55-9 - PubMed
  3. Eur J Cancer. 2013 May;49(7):1752-60 - PubMed
  4. Anticancer Drugs. 1993 Jun;4(3):311-5 - PubMed
  5. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jul 24;839(1-2):45-53 - PubMed
  6. Cancer. 1991 Aug 1;68(3):499-501 - PubMed
  7. Gan To Kagaku Ryoho. 2013 Apr;40(4):483-7 - PubMed
  8. Chemotherapy. 2010;56(4):313-7 - PubMed
  9. Br J Cancer. 1997;75(3):464-5 - PubMed
  10. Anticancer Res. 2006 Sep-Oct;26(5B):3983-8 - PubMed
  11. Jpn J Clin Oncol. 2012 Aug;42(8):686-90 - PubMed
  12. J Clin Oncol. 1999 Apr;17(4):1105 - PubMed
  13. Nature. 1957 Mar 30;179(4561):663-6 - PubMed
  14. Clin Cancer Res. 2000 Dec;6(12):4705-12 - PubMed
  15. Cancer. 2012 Jun 1;118(11):2935-43 - PubMed
  16. Cancer Chemother Pharmacol. 2014 Oct;74(4):757-63 - PubMed

Publication Types